

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 08 DEC 1999

WIPO

PCT

Applicant's or agent's file reference
2118060/EJH/AJB**FOR FURTHER
ACTION**See Notification of Transmittal of International Preliminary
Examination Report (Form PCT/IPEA/416).

International application No.

PCT/AU 98/00902

International filing date (day/month/year)

30 October 1998

Priority Date (day/month/year)

31 October 1997

International Patent Classification (IPC) or national classification and IPC

Int. Cl.⁶ C12N 15/12, C07K 14/00, A61K 38/17

Applicant

INTERNATIONAL DIABETES INSTITUTE *et al*

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.
- ☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheet(s).

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand
3 May 1999

Name and mailing address of the IPEA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaaustralia.gov.au
Facsimile No. (02) 6285 3929Date of completion of the report
2 December 1999

Authorized Officer

J.H. CHAN

Telephone No. (02) 6283 2340

FEB 16 2000

TECH CENTER 1600/2900

I. Basis of the report1. With regard to the **elements** of the international application:*

- ☐ the international application as originally filed.
- ☒ the description, pages **1-46** as originally filed,
pages , filed with the demand,
pages , filed with the letter of .
- ☒ the claims, pages **55-57** as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages , filed with the letter of .
- ☒ the drawings, fig/sheets **1A/1-9B/17, 11A/20-15/25** as originally filed,
pages , filed with the demand,
pages **9C/18-10C/19** filed with the letter of **23 November 1999**.
- ☒ the sequence listing part of the description:
pages **47-54** as originally filed
pages , filed with the demand
pages , filed with the letter of .

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, was on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are not annexed to this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 2-19	YES
	Claims 1	NO
Inventive step (IS)	Claims 2-19	YES
	Claims 1	NO
Industrial applicability (IA)	Claims 1-19	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

D1 Bray G. A. Amer. J Clinical Nutrition 1992:55:265S-271S.

D2 Frankish H. M. *et al* Peptides 1995: 16(4): 757-771.

Novelty and inventive step:

Document D1 does not disclose nucleic acids molecules, protein and their use as defined in claims 1-19, as such the invention so defined is novel and inventive.

Document D2 (Frankish *et al*) teaches that the neuropeptide Y (NPY) is found in the hypothalamus of obese mice at higher amount than in ordinary mice. (Passages entitled "NPY in hyperinsulinemic/obese diabetes syndromes" and "NPU in insulin-deficient diabetes" on Page 763). Further the nucleic and amino acid sequences of NPY are known (see Neuropeptide Y: An introduction, on page 760 supra). For these reasons the invention as defined in claim 1 is not novel and lacks an inventive step.

Industrial applicability:

The invention as defined in claims 1-19 is useful in therapy and diagnosis in human health, as such it is deemed to have industrial applicability.

18/25




Fig.9C




Fig.10A

* = significant, $p < 0.05$

19/25




Fig.10B




Fig.10C

* = significant, $p < 0.05$

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum)

21118060/EJH

Box No. I TITLE OF INVENTION

A NOVEL GENE AND USES THEREFOR

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

INTERNATIONAL DIABETES INSTITUTE
260 Kooyong Road
CAULFIELD SOUTH 3162
VICTORIA
AUSTRALIA

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (that is, country) of nationality:
AUSTRALIA

State (that is, country) of residence:
AUSTRALIA

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

DEAKIN UNIVERSITY
Pigdons Road
WAURN PONDS 3221
VICTORIA
AUSTRALIA

This person is:

☒ applicant only

☐ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
AUSTRALIA

State (that is, country) of residence:
AUSTRALIA

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

HUGHES, E John L
SLATTERY, John M
CAINE, Michael J

DAVIES COLLISON CAVE
1 Little Collins Street
MELBOURNE 3000
VICTORIA
AUSTRALIA

Telephone No.

+61 3 9254 2777

Facsimile No.

+61 3 9254 2770

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)	
<i>If none of the following sub-boxes is used, this sheet should not be included in the request.</i>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p> <p>ZIMMET, Paul Zev 24 Linlithgow Road TOORAK 3142 VICTORIA AUSTRALIA</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality: AUSTRALIA	State (that is, country) of residence: AUSTRALIA
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p> <p>COLLIER, Gregory 22 Kestrel Place OCEAN GROVE 3226 VICTORIA AUSTRALIA</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality: AUSTRALIA	State (that is, country) of residence: AUSTRALIA
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality:	State (that is, country) of residence:
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality:	State (that is, country) of residence:
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality:	State (that is, country) of residence:
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p><input type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.</p>	

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes, at least one must be marked):

Regional Patent:

- ☒ AP ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria | |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GW Guinea-Bissau | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> JP Japan | |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> YU Yugoslavia |
| | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |
| <input checked="" type="checkbox"/> LC Saint Lucia | |
| <input checked="" type="checkbox"/> LK Sri Lanka | |
| <input checked="" type="checkbox"/> LR Liberia | |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

- ☒ ... Grenada
- ☐

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the fee for designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Box No. VI PRIORITY CLAIM ☐ Further priority claims are indicated in the Supplemental Box.

Filing date of earlier application (da: month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application: regional Office	international application: receiving Office
item (1) (31.10.97) 31 October 1997	PP 0117	Australia		
item (2) (11.11.97) 11 November 1997	PP 0323	Australia		
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): 1 + 2

* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used): ISA /	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):		
	Date (day/month/year)	Number	Country (or regional Office)

Box No. VIII CHECK LIST; LANGUAGE OF FILING


This international application contains the following number of sheets: request : 4 description (excluding sequence listing part) : 54 claims : 3 abstract : 1 drawings : 17 sequence listing part of description : Total number of sheets : 79	This international application is accompanied by the item(s) marked below:		
	1. <input type="checkbox"/> fee calculation sheet	2. <input type="checkbox"/> separate signed power of attorney	3. <input type="checkbox"/> copy of general power of attorney; reference number, if any:
	4. <input type="checkbox"/> statement explaining lack of signature	5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):	6. <input type="checkbox"/> translation of international application into (language):
	7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material	8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form	9. <input type="checkbox"/> other (specify):

Figure of the drawings which should accompany the abstract: None	Language of filing of the international application: English
--	--

Box No. IX SIGNATURE OF APPLICANT OR AGENT (See Supplemental Box No. IX)

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

INTERNATIONAL DIABETES INSTITUTE

By: 

Name:
Position: Professor / Director

DEAKIN UNIVERSITY

By: 

Name: R. H. ELLIOTT
Position: VICE-PRESIDENT (ADMINISTRATION)

For receiving Office use only		2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
1. Date of actual receipt of the purported international application:		
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

For International Bureau use only


Date of receipt of the record copy by the International Bureau:


Supplemental Box

If the Supplemental Box is not used, this sheet should not be included in the request.

1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:
 - (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
 - (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
 - (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
 - (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
 - (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
 - (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
 - (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.
2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.
3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

Continuation of Box No. IX


 ZIMMET, Paul Zimet


 COLLIER, Gregory



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/00, A61K 38/17	A1	(11) International Publication Number: WO 99/23217 (43) International Publication Date: 14 May 1999 (14.05.99)
(21) International Application Number: PCT/AU98/00902 (22) International Filing Date: 30 October 1998 (30.10.98) (30) Priority Data: PP 0117 31 October 1997 (31.10.97) AU PP 0323 11 November 1997 (11.11.97) AU <i>31 June 99</i> (71) Applicants (for all designated States except US): INTERNATIONAL DIABETES INSTITUTE [AU/AU]; 260 Kooyong Road, Caulfield South, VIC 3162 (AU). DEAKIN UNIVERSITY [AU/AU]; Pigdons Road, Waurm Ponds, VIC 3221 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): ZIMMET, Paul, Zev [AU/AU]; 24 Linlithgow Road, Toorak, VIC 3142 (AU). COLLIER, Gregory [AU/AU]; 22 Kestrel Place, Ocean Grove, VIC 3226 (AU). (74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A NOVEL GENE AND USES THEREFOR (57) Abstract The present invention relates generally to a nucleic acid molecule which encodes a protein associated with the modulation of obesity, diabetes and metabolic energy levels. More particularly, the present invention is directed to a nucleic acid molecule and a recombinant and purified naturally occurring protein encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecule and protein and their derivatives, homologues, analogues and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

A NOVEL GENE AND USES THEREFOR

FIELD OF THE INVENTION

5 The present invention relates generally to a nucleic acid molecule which encodes a protein associated with the modulation of obesity, diabetes and metabolic energy levels. More particularly, the present invention is directed to a nucleic acid molecule and a recombinant and purified naturally occurring protein encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid
10 molecule and protein and their derivatives, homologues, analogues and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a
15 stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Bibliographic details of the publications referred by author in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and
20 amino acid sequences referred to in the specification are defined following the bibliography.

BACKGROUND OF THE INVENTION

The increasing sophistication of recombinant DNA technology is greatly facilitating research and
25 development in the medical, veterinary and allied human and animal health fields. This is particularly the case in the investigation of the genetic bases involved in the etiology of certain disease conditions. One particularly significant condition from the stand point of morbidity and mortality is obesity and its association with non-insulin-dependent diabetes mellitus (NIDDM) and cardiovascular disease.

30

Obesity is defined as a pathological excess of body fat and is the result of an imbalance between

- 2 -

energy intake and energy expenditure for a sustained period of time. Obesity is the most common metabolic disease found in affluent societies. The prevalence of obesity in these nations is alarmingly high, ranging from 10% to upwards of 50% in some subpopulations (Bouchard, 1994). Of particular concern is the fact that the prevalence of obesity appears to be rising consistently in affluent societies and is now increasing rapidly in less prosperous nations as they become more affluent and/or adopt cultural practices from the more affluent countries (Zimmet, 1992).

In Australia, for example, studies using the definition of obesity of BMI>30 have found prevalence rates for obesity of 8.2-9.3% in men and 9.1-11.1% in women (Risk Factor Prevalence Study Management Committee, 1990; Waters and Bennett 1995). The prevalence rates for obesity are increasing in Australia, as they are in many affluent societies. Bennett and Magnus (1994) found that the mean weight of Australian females aged 20-69 increased by 3.1 kg (from 61.7 to 64.8 kg) from 1980 to 1989, while the corresponding increase in males was 1.8 kg (from 77.0 to 78.8 kg). No change in height was observed during this period. Accordingly, the crude prevalence rates of obesity increased from 8.0 to 13.2% in females and from 9.3 to 11.5% in males (Bennett and Magnus 1994). All of the above changes were statistically significant ($p<0.05$).

The high and increasing prevalence of obesity has significant health implications. Obesity has been identified as a key risk indicator of preventable morbidity and mortality due to disease such as NIDDM and cardiovascular disease (National Health and Medical Research Council, 1996). The annual costs of obesity in Australia, for example, associated with these and other disease conditions have been conservatively estimated at AU\$810 million (National Health and Medical Research Council, 1996).

A genetic basis for the etiology of obesity is indicated *inter alia* from studies in twins, adoption studies and population-based analyses which suggest that genetic effects account for 25-80% of the variation in body weight in the general population (Bouchard 1994; Kopelman *et al*, 1994; Ravussin, 1995). It is considered that genes determine the possible range of body weight in an individual and then the environment influences the point within this range where the individual

- 3 -

is located at any given time (Bouchard, 1994).

Obesity is a complex and heterogeneous disorder and of considerable relevance to society. However, despite numerous studies into genes thought to be involved in the pathogenesis of obesity, there have been surprisingly few significant findings in this area. In addition, genome-wide scans in various population groups have not produced definitive evidence of the chromosomal regions having a major effect on obesity.

The hypothalamus has long been recognised as a key brain area in the regulation of energy intake. Early studies led to the dual-centre hypothesis which proposed that two opposing centres in the hypothalamus were responsible for the initiation and termination of eating, the lateral hypothalamus (LHA; "hunger centre") and ventromedial hypothalamus (VMH; "satiety centre"; Stellar 1954). The dual-centre hypothesis has been repeatedly modified to accommodate the increasing information about the roles played by various other brain regions, neurotransmitter systems, and hormonal and neural signals originating in the gut on the regulation of food intake. In addition to the LHA and VMH, the paraventricular nucleus (PVN) is now considered to have an important integrative function in the control of energy intake.

A large number of neurotransmitters have been investigated as possible hypothalamic regulators of feeding behaviour including neuropeptide Y (NPY), glucagon-like peptide 1 (GLP-1), melanin-concentrating hormone (MCH), serotonin, cholecystokinin and galanin. Some of these neurotransmitters stimulate food intake, some act in an anorexigenic manner and some have diverse effects on energy intake depending on the site of administration. For example, gamma-aminobutyric acid (GABA) inhibits food intake when injected into the LHA, but stimulates eating when injected into the VMH or PVN (Leibowitz, 1985). Feeding behaviour is thought to be greatly influenced by the interaction of stimulatory and inhibitory signals in the hypothalamus.

In work leading up to the present invention, the inventors have made a significant break through in determining a genetic basis of obesity by identifying a genetic sequence differentially expressed in lean and obese animals. In accordance with the present invention, the inventors have isolated a novel gene which is proposed to be associated with energy balance and also in modulating

obesity and diabetes.

SUMMARY OF THE INVENTION

- 5 One aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a protein or a derivative, homologue, analogue or mimetic thereof wherein said nucleic acid molecule is expressed in larger amounts in hypothalamus tissue of obese animals compared to lean animals.
- 10 Another aspect of the present invention is directed to a nucleic acid molecule comprising a nucleotide sequence, or a complementary form thereof, encoding an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:14 or an amino acid sequence having at least 30% similarity to all or a part thereof or a mimetic or said amino acid sequence or a nucleotide sequence capable of hybridizing to said nucleic acid molecule under low stringency
- 15 conditions at 42°C and wherein said nucleic acid molecule is expressed in a larger amount in hyperthalamus tissue of obese animals compared to lean animals.

Yet another aspect of the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding a protein or a

20 derivative, homologue, analogue or mimetic thereof wherein said nucleotide sequence is as substantially set forth in SEQ ID NO:1 or SEQ ID NO:13 or a nucleotide sequence having at least about 30% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:13 and/or is capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C and wherein said nucleic acid molecule is expressed in a larger amount in hyperthalamus tissue of

25 obese animals compared to lean animals.

Still yet another aspect of the present invention provides an isolated protein or a derivative, homologue, analogue or mimetic thereof which is produced in a larger amount in hyperthalamus tissue of obese animals compared to lean animals.

30

In yet another aspect of the present invention, there is provided an isolated protein or a

- 5 -

derivative, homologue, analogue or mimetic thereof wherein said protein comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:14 or an amino acid sequence having at least 30% similarity to all or part of SEQ ID NO:2 or SEQ ID NO:14 and wherein said protein is produced in a larger amount in hyperthalamus tissue of obese animals
5 compared to lean animals.

A further aspect of the present invention is directed to an isolated protein or a derivative, homologue, analogue or mimetic thereof wherein said protein is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:13 or a nucleotide sequence
10 having at least 60% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:13 and/or is capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C.

The protein of the present invention is referred to as "beacon" and the nucleotide sequence encoding beacon is referred to as the *beacon* gene.
15

A further aspect of the present invention relates to a composition comprising beacon or its derivatives, homologues, analogues or mimetics or agonists or antagonists of beacon together with one or more pharmaceutically acceptable carriers and/or diluents.

20 Yet a further aspect of the present invention contemplates a method for treating a subject comprising administering to said subject a treatment effective amount of beacon or a derivative, homologue, analogue or mimetic thereof or a genetic sequence encoding same or an agonist or antagonist of beacon or *beacon* gene expression for a time and under conditions sufficient to effect treatment.

25 In accordance with this and other aspects of the present invention, treatments contemplated herein include but are not limited to obesity, anorexia, weight maintenance, energy imbalance and diabetes. Treatment may be by the administration of a pharmaceutical composition or genetic sequences *via* gene therapy. Treatment is contemplated for human subjects as well as animals
30 such as animals important to livestock industry.

- 6 -

Still yet another aspect of the present invention is directed to a diagnostic agent for use in monitoring or diagnosing conditions such as but not limited to obesity, anorexia, weight maintenance, energy imbalance and/or diabetes, said diagnostic agent selected from an antibody to beacon or its derivatives, homologues, analogues or mimetics and a genetic sequence useful
5 in PCR, hybridization, RFLP amongst other techniques.

A summary of SEQ ID NOs used throughout the subject specification is provided in Table 1.

- 7 -

TABLE 1

	SEQ ID NO.	DESCRIPTION
	1	Nucleotide sequence for <i>beacon</i>
5	2	Amino acid sequence for beacon
	3	Complementary sequence for SEQ ID NO:1
	4	Primer sequence
	5	Primer sequence
	6	Primer sequence
10	7	Primer sequence
	8	Primer sequence
	9	Primer sequence
	10-12	Primer and probe sequences used for <i>beacon</i> gene expression studies
	13	Nucleotide sequence for human <i>beacon</i>
15	14	Amino acid sequence for human beacon ("short" form of beacon)

A summary of the single and three letter abbreviations for amino acid residues used in the present specification is provided in Table 2.

- 8 -

TABLE 2

5	Amino Acid	Three-letter Abbreviation	One-letter Symbol
	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
10	Aspartic acid	Asp	D
	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glycine	Gly	G
15	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
20	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
	Tryptophan	Trp	W
25	Tyrosine	Tyr	Y
	Valine	Val	V
	Any residue	Xaa	X

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a representation showing the nucleotide sequence of both strands of a differentially expressed band in hypothalamus tissue of lean and obese *Psammomys obesus* corresponding to
5 *beacon*. The amino acids encoded by each codon are shown above in single letter code and the numbering refers to the amino acid position from the start codon.

Figure 1B is a representation of a nucleotide and corresponding amino acid sequence of human
beacon. Human *beacon* is a "short" form of *Psammomys obesus beacon* except that amino acid
10 15 may be His or Arg. The corresponding codon may be CGC or CAC, respectively.

Figure 2 is a representation showing (A). Amino acid alignments of *beacon* with putative human, mouse, *Caenorhabditis elegans*, *Fasciola hepatica*, rice and *Saccharomyces cerevisiae* gene products. (B). Amino acid alignments of *beacon* with human ubiquitin and ubiquitin-like protein
15 8 from *Arabidopsis thaliana*. Identical amino acids are marked with a line and plus signs indicate deletions are indicated by forward slashes. A spliced leader sequence in the *F. hepatica*-- gene did not allow the aminoterminal amino acids to be compared.

Figure 3 is a graphical representation showing correlations of hypothalamic *beacon* gene
20 expression with (A) body weight and (B) log plasma insulin concentrations in *Psammomys obesus*.

Figure 4 is a graphical representation showing improved correlations of hypothalamic *beacon* gene expression with (A) body weight and (B) log plasma insulin concentrations in leptin-treated
25 *Psammomys obesus*.

Figure 5 is a graphical representation showing correlations of *beacon* gene expression in adipose tissue with (A) body weight and (B) log plasma insulin, and in liver with (C) body weight and (D) log plasma insulin.

30

Figure 6 is a graphical representation showing effects of leptin treatment on hypothalamic

beacon gene expression in lean and obese *Psammomys obesus*.

Figure 7 is a graphical representation showing effects of leptin treatment on adipose tissue *beacon* gene expression in lean and obese *Psammomys obesus*. (*p=0.014 compared with lean control animals).

Figure 8 is a graphical representation showing effects of nicotine treatment on (A) hypothalamic and (B) adipose tissue *beacon* gene expression in lean and obese *Psammomys obesus*.

Figure 9 is a graphical representation of (A) food intake per day; (B) cumulative food intake; and (C) body weight change in *Psammomys obesus* over an 8 day period administered with *beacon* or saline.

Figure 10 is a graphical representation showing food intake per day in (A) Group A *Psammomys obesus*; (B) Group B *Psammomys obesus* and (C) Group C *Psammomys obesus* administered with *beacon* or saline.

Figure 11 is a graphical representation showing cumulative food intake over a 8 day period in (A) Group A *Psammomys obesus*; (B) Group B *Psammomys obesus*; and (C) Group C *Psammomys obesus* administered with *beacon* or saline.

Figure 12 is a graphical representation showing *beacon* gene expression verses (A) body weight; and (B) percentage body fat in Group A *Psammomys obesus*.

Figure 13 is a graphical representation showing *beacon* gene expression verses percentage body fat in (A) Group A *Psammomys obesus*; (B) Group B *Psammomys obesus*; and (C) Group C *Psammomys obesus*.

Figure 14 is a graphical representation showing *beacon* gene expression in Group A, B and C *Psammomys obesus*.

- 11 -

Figure 15 is a graphical representation showing beacon gene expression verses log insulin in Group A, B and C *Psammomys obesus* animals.

- 12 -

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the identification of a novel gene associated *inter alia* with regulation of energy balance obesity and diabetes. The gene was identified following
5 differential screening of hypothalamic mRNA between lean and obese animals.

Accordingly, one aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotide encoding or complementary to a sequence encoding a protein or a derivative homologue, analogue or mimetic thereof wherein said nucleic acid molecule is
10 expressed in a larger amount in hypothalamus tissue of obese animals compared to lean animals.

The terms "lean" and "obese" are used in their most general sense but should be considered relative to the standard criteria for determining obesity. Generally, for human subjects the definition of obesity is BMI>30 (Risk Factor Prevalence 1990; Waters and Bennett, 1995).
15

Conveniently, an animal model may be employed to study the effects of obese and lean animals. In particular, the present invention is exemplified using the *Psammomys obesus* (the Israeli sand rat) animal model of dietary-induced obesity and NIDDM. In its natural desert habitat, an active lifestyle and saltbush diet ensure that they remain lean and normoglycemic (Shafrir and Gutman,
20 1993). However, in a laboratory setting on a diet of *ad libitum* chow (on which many other animal species remain healthy), a range of pathophysiological responses are seen (Barnett *et al*, 1994a, b; Barnett *et al*, 1995). By the age of 16 weeks, more than half of the animals become obese and approximately one third develop NIDDM. Only hyperphagic animals go on to develop hyperglycemia, highlighting the importance of excessive energy intake in the pathophysiology
25 of obesity and NIDDM in *Psammomys obesus* (Collier *et al*, 1997a; Walder *et al*, 1997a). Other phenotypes found include hyperinsulinemia, dyslipidemia and impaired glucose tolerance (Collier *et al*, 1997a, b). *Psammomys obesus* exhibit a range of bodyweight and blood glucose and insulin levels which forms a continuous curve that closely resembles the patterns found in human populations, including the inverted U-shaped relationship between blood glucose and insulin
30 levels known as "Starling's curve of the pancreas" (Barnett *et al*, 1994a; DeFronzo, 1988). It is the heterogeneity of the phenotypic response of *Psammomys obesus* which make it an ideal

- 13 -

model to study the etiology and pathophysiology of obesity and NIDDM.

A preferred embodiment of the present invention is directed to a nucleic acid molecule comprising a nucleotide sequence or a complementary form thereof encoding an amino acid
5 sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:14 or an amino acid sequence having at least 60% similarity to all or a part thereof or is a mimetic thereof or a nucleotide sequence capable of hybridizing to said nucleic acid molecule under low stringency conditions at 42°C and wherein said nucleic acid molecule is expressed in larger amounts in hyperthalamus tissue of obese animals compared to lean animals.

10

Another embodiment of the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding a protein or a derivative, homologue, analogue or mimetic thereof wherein said nucleotide sequence is as substantially set forth in SEQ ID NO:1 or SEQ ID NO:13 or a nucleotide sequence having at
15 least about 60% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:13 and/or is capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C and wherein said nucleic acid molecule is expressed in a larger amount in hyperthalamus tissue of obese animals compared to lean animals.

20 Reference herein to similarity is generally at a level of comparison of at least 15 consecutive or substantially consecutive nucleotides or at least 5 consecutive or substantially consecutive amino acid residues.

The term "similarity" as used herein includes exact identity between compared sequences at the
25 nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational
30 levels. In a particularly preferred embodiment, nucleotide and sequence comparisons are made at the level of identity rather than similarity. Any number of programs are available to compare

- 14 -

nucleotide and amino acid sequences. Preferred programs have regard to an appropriate alignment. One such program is Gap which considers all possible alignment and gap positions and creates an alignment with the largest number of matched bases and the fewest gaps. Gap uses the alignment method of Needleman and Wunsch (1970). Gap reads a scoring matrix that
5 contains values for every possible GCG symbol match. GAP is available on ANGIS (Australian National Genomic Information Service) at website <http://mell.angis.org.au>.

Reference herein to a low stringency at 42°C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for
10 hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and
15 encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

The nucleotide sequence or amino acid sequence of the present invention may correspond to
20 exactly the same sequence of the naturally occurring gene (or corresponding cDNA) or protein or may carry one or more nucleotide or amino acid substitutions, additions and/or deletions. The nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:13 corresponds to a new gene referred to herein as "*beacon*". The corresponding protein is "*beacon*". Reference herein to *beacon* includes, where appropriate, reference to the genomic gene or cDNA as well as any
25 naturally occurring or induced derivatives. Apart from the substitutions, deletions and/or additions to the nucleotide sequence, the present invention further encompasses mutants, fragments, parts and portions of the nucleotide sequence corresponding to *beacon*. One useful form of a *beacon* encodes a "short" form of beacon. The short form of beacon corresponds to human beacon. The preferred short form of beacon is 33 amino acids in length. Such a short
30 form can also be readily synthesised *in vitro*.

- 15 -

A homologue is considered to be a *beacon* gene from another animal species. The *beacon* gene is exemplified herein from *Psammomys obesus* hypothalamus. The invention extends, however, to the homologous gene, as determined by nucleotide sequence and/or function, from humans, primates, livestock animals (eg. cows, sheep, pigs, horses, donkeys), laboratory test animals (eg. mice, guinea pigs, hamsters, rabbits), companion animals (eg. cats, dogs) and captured wild animals (eg. rodents, foxes, deer, kangaroos).

The nucleic acid of the present invention and in particular *beacon* and its derivatives and homologues may be in isolated or purified form and/or may be ligated to a vector such as an expression vector. Expression may be in a eukaryotic cell line (eg. mammalian, insect or yeast cells) or in microbial cells (eg. *E. coli*) or both.

The derivatives of the nucleic acid molecule of the present invention include oligonucleotides, PCR primers, antisense molecules, molecules suitable for use in co-suppression and fusion nucleic acid molecules. Ribozymes and DNA enzymes are also contemplated by the present invention directed to *beacon* or its mRNA. Derivatives and homologues of *beacon* are conveniently encompassed by those nucleotide sequences capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 or 3 under low stringency conditions at 42°C.

Another aspect of the present invention provides an isolated protein or a derivative, homologue, analogue or mimetic thereof which is produced in larger amounts in hyperthalamus tissue in obese animals compared to lean animals.

In a more preferred aspect of the present invention, there is provided an isolated protein or a derivative, homologue, analogue or mimetic thereof wherein said protein comprises an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:14 or an amino acid sequence having at least 60% similarity to all or part of SEQ ID NO:2 or SEQ ID NO:14 and wherein said protein is produced in larger amounts by hyperthalamus tissue of obese animals compared to lean animals.

A further aspect of the present invention is directed to an isolated protein or a derivative,

- 16 -

homologue, analogue or mimetic thereof wherein said protein is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:13 or a nucleotide sequence having at least 60% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:13 and/or is capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C.

5

The protein of this aspect of the present invention is beacon. A truncated form of beacon is referred to as a "short form". The preferred short form is 33 amino acids in length.

Reference herein to beacon includes reference to isolated or purified naturally occurring beacon
10 protein molecules as well as any derivatives, homologues, analogues and mimetics thereof. Derivatives includes parts, fragments and portions of beacon as well as single and multiple amino acid substitutions, deletions and/or additions to beacon. A derivative of beacon is conveniently encompassed by molecules encoded by a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C.

15

Other derivatives of beacon include chemical analogues. Analogues of beacon contemplated-
herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous
20 molecule or their analogues.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic
25 anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

30 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

- 17 -

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

5 Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

10

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

15

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis
20 include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 3.

25

TABLE 3

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane- carboxylate	Cpro	L-N-methylasparagine	Nmasn
			L-N-methylaspartic acid	Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl- carboxylate	Norb	L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
	cyclohexylalanine		Chexa L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
15	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Das	L-N-methylmethionine	Nmmt
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
30	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva

- 19 -

	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
5	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
10	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
15	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
20	D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
25	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
30	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp

- 20 -

	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
5	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- <i>n</i> -naphthylalanine	Nmanap
10	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
15	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
20	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methyllleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
25	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr

- 21 -

L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbanylmethyl)glycine		carbanylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
5 ethylamino)cyclopropane			

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(\text{CH}_2)_n$ spacer groups with $n=1$ to $n=6$,
 10 glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α -methylamino acids, introduction of double bonds between C_α and C_β atoms of amino acids and
 15 the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

All such modifications may also be useful in stabilizing the beacon molecule for use in *in vivo*
 20 administration protocols or for diagnostic purposes.

The identification of beacon permits the generation of a range of therapeutic molecules capable of modulating expression of beacon or modulating the activity of beacon. Modulators contemplated by the present invention includes agonists and antagonists of beacon expression.
 25 Antagonists of beacon expression include antisense molecules, ribozymes and co-suppression molecules. Agonists include molecules which increase promoter activity or which interfere with negative regulatory mechanisms. Antagonists of beacon include antibodies and inhibitor peptide fragments. All such molecules may first need to be modified to enable such molecules to penetrate cell membranes. Alternatively, viral agents may be employed to introduce genetic
 30 elements to modulate expression of *beacon*. In so far as beacon acts in association with other genes such as the *ob* gene which encodes leptin, the therapeutic molecules may target both the

- 22 -

beacon and *ob* genes or their translation products.

The present invention contemplates, therefore, a method for modulating expression of *beacon* in a mammal, said method comprising contacting the *beacon* gene with an effective amount of a modulator of *beacon* expression for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of *beacon*. For example, a nucleic acid molecule encoding *beacon* or a derivative or homologue thereof may be introduced into a cell to enhance the ability of that cell to produce beacon, conversely, *beacon* antisense sequences such as oligonucleotides may be introduced to decrease the availability of beacon molecules.

10

Another aspect of the present invention contemplates a method of modulating activity of beacon in a mammal, said method comprising administering to said mammal a modulating effective amount of a molecule for a time and under conditions sufficient to increase or decrease beacon activity. The molecule may be a proteinaceous molecule or a chemical entity and may also be a derivative of beacon or its ligand.

Modulating levels of *beacon* expression is important in the treatment of a range of conditions such as obesity, anorexia, energy imbalance, diabetes, metabolic syndrome, dyslipidemia, hypertension and insulin resistance. It may also be useful in the agricultural industry to assist in the generation of leaner animals, or where required, more obese animals. Accordingly, the mammal contemplated by the present invention includes but is not limited to humans, primates, livestock animals (eg. pigs, sheep, cows, horses, donkeys), laboratory test animals (eg. mice, rats, guinea pigs, hamsters, rabbits), companion animals (eg. dogs, cats) and captured wild animals (eg. foxes, kangaroos, deer). A particularly preferred host is a human, primate or livestock animal.

Accordingly, the present invention contemplates in one embodiment a composition comprising a modulator of *beacon* expression or beacon activity and one or more pharmaceutically acceptable carriers and/or diluents. In another embodiment, the composition comprises beacon or a derivative, homologue, analogue or mimetic thereof and one or more pharmaceutically acceptable carriers and/or diluents. The compositions may also comprise leptin or modulations

- 23 -

of leptin activity or *ob* expression.

For brevity, all such components of such a composition are referred to as "active components".

- 5 The compositions of active components in a form suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of
- 10 microorganisms such as bacteria and fungi.

The carrier can be a solvent or other medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

15

- The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about
- 20 by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

- Sterile injectable solutions are prepared by incorporating the active components in the required amount in the appropriate solvent with optionally other ingredients, as required, followed by
- 25 sterilization by, for example, filter sterilization, irradiation or other convenient means. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

30

When *beacon* and beacon including beacon itself are suitably protected they may be orally

- 24 -

administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, 5 buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be 10 obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 μ g and 2000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: A binder such 15 as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a 20 liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form 25 should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion 30 media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known

- 25 -

in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

- 5 It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for
- 10 the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

15

The principal active component may be compounded for convenient and effective administration in sufficient amounts with a suitable pharmaceutically acceptable carrier in dosage unit form. A unit dosage form can, for example, contain the principal active component in amounts ranging from 0.5 μ g to about 2000 mg. Expressed in proportions, the active compound is

20 generally present in from about 0.5 μ g to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

In general terms, effective amounts of beacon will range from 0.01 ng/kg/body weight to above

25 10,000 mg/kg/body weight. Alternative amounts range from 0.1 ng/kg/body weight to above 1000 mg/kg/body weight. Beacon may be administered per minute, hour, day, week, month or year depending on the condition being treated. The route of administration may vary and includes intravenous, intraperitoneal, sub-cutaneous, intramuscular, intranasal, *via* suppository, *via* infusion, *via* drip, orally or *via* other convenient means.

30

The pharmaceutical composition may also comprise genetic molecules such as a vector capable

- 26 -

of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating *beacon* expression or beacon activity. The vector may, for example, be a viral vector.

- 5 Still another aspect of the present invention is directed to antibodies to beacon and its derivatives and homologues. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to beacon or may be specifically raised to beacon or derivatives or homologues thereof. In the case of the latter, beacon or its derivatives or homologues may first need to be associated with a carrier molecule. The antibodies and/or
- 10 recombinant beacon or its derivatives of the present invention are particularly useful as therapeutic or diagnostic agents.

For example, beacon and its derivatives can be used to screen for naturally occurring antibodies to beacon which may occur in certain autoimmune diseases or where cell death is occurring.

- 15 These may occur, for example in some autoimmune diseases. Alternatively, specific antibodies can be used to screen for beacon. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA.

- Antibodies to beacon of the present invention may be monoclonal or polyclonal and may be
- 20 selected from naturally occurring antibodies to the beacon or may be specifically raised to the beacon or its derivatives. In the case of the latter, the beacon protein may need first to be associated with a carrier molecule. Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include
- 25 fragments and hybrids of antibodies. The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a diagnostic tool or as a means for purifying beacon.

- 27 -

For example, specific antibodies can be used to screen for beacon proteins. The latter would be important, for example, as a means for screening for levels of beacon in a cell extract or other biological fluid or purifying beacon made by recombinant means from culture supernatant fluid. Techniques for the assays contemplated herein are known in the art and include, for
5 example, sandwich assays and ELISA.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used
10 with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of beacon.

Both polyclonal and monoclonal antibodies are obtainable by immunization with the enzyme or protein and either type is utilizable for immunoassays. The methods of obtaining both types
15 of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of beacon, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoabsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the
20 potential heterogeneity of the product.

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell
25 line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. (See, for example Douillard and Hoffman, Basic Facts about Hybridomas, in *Compendium of Immunology* Vol II, ed. by Schwartz, 1981; Kohler and Milstein, *Nature* 256: 495-499, 1975; *European Journal of Immunology* 6: 511-519, 1976).

30

Another aspect of the present invention contemplates a method for detecting beacon or a

- 28 -

derivative or homologue thereof in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for beacon or its antigenic derivatives or homologues for a time and under conditions sufficient for a complex to form, and then detecting said complex.

5

The presence of the complex is indicative of the presence of beacon. This assay may be quantitated or semi-quantitated to determine a propensity to develop obesity or other conditions or to monitor a therapeutic regimen.

- 10 The presence of beacon may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4, 424,279 and 4,018,653. These, of course, includes both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a
- 15 labelled antibody to a target.

Sandwich assays are among the most useful and commonly used assays. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid

20 substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-beacon complex, a second antibody specific to the beacon, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of another complex of antibody-beacon-labelled antibody. Any

25 unreacted material is washed away, and the presence of the beacon is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound

30 antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is

- 29 -

one which might contain beacon including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

5

The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from room temperature to about 37°C) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of beacon. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to beacon.

An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

- 30 -

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. A "reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The present invention also contemplates genetic assays such as involving PCR analysis to detect *beacon* or its derivatives.

- 31 -

The assays of the present invention may also extend to measuring *beacon* or beacon in association with *ob* or leptin.

The present invention is further described by reference to the following non-limiting Examples.

- 32 -

EXAMPLE 1**Animals**

A *Psammomys obesus* colony is maintained at Deakin University, with the breeding pairs fed
5 *ad libitum* a diet of lucerne and chow. Experimental animals were weaned at four weeks of age
and given a diet of standard laboratory chow from which 12% of energy was derived from fat,
63% from carbohydrate and 25% from protein (Barastoc, Pakenham, Australia). Animals were
housed individually in a temperature controlled room ($22 \pm 1^\circ\text{C}$) with a 12-12-hour light-dark
cycle. The animals used in the study were aged 16-20 weeks during the pretreatment period.
10 A total of 30 *Psammomys obesus* were investigated in this study, of which 10 were treated with
leptin as described below and 20 were used as controls (treated with saline only).

EXAMPLE 2**Leptin Treatment**

15

A group of lean and obese *Psammomys obesus* were followed for a 7-day period with free
access to food and water to establish baseline data for food intake (measured by the rate of
disappearance), body weight, blood glucose and plasma insulin concentrations. After the
baseline period, the animals were given intraperitoneal injections three times per day (at 0800,
20 1600 and 2400) of 15 mg leptin per kg body weight, or equivalent volume of saline for control
animals, for a total of 7 days. This dosage of leptin resulted in a total of 45 mg/kg/day. Body
weight and food intake were measured daily throughout the study. In addition, blood was
collected from the animals on days 2, 4 and 7 at midday (the midpoint between the morning and
afternoon injections) for biochemical analyses. The results clearly demonstrated that leptin was
25 effective in reducing body weight and food intake in the lean animals, however, the obese
animal remained leptin resistant and demonstrated no differences in food intake or body weight
(Walder et al 1997b).

30

- 33 -

EXAMPLE 3**Nicotine treatment**

As described above for the leptin treatment, animals were followed for a 1 week run in period
5 before being allocated to either infusion with 12mg/day nicotine or vehicle control infusion for
7 days. All infusions were *via* mini-osmotic pumps implanted subcutaneously (Alza, California,
USA). Nicotine treatment resulted in a significant reduction in food intake and body weight,
this effect was more pronounced than the effect of leptin described above and occurred in both
lean and obese animals.

10

At the completion of either study the animals were killed by anaesthetic overdose (120 mg/kg
pentobarbitone) and selected fat depots (interscapular, perirenal, epididymal, mesenteric and
intramuscular) were removed and weighed to allow an estimate of body fat content. The
weights of the various fat depots were combined and divided by total body mass to provide this
15 estimate.

20

All of the experiments described above were carried out following the Australian NHMRC
principles of laboratory animal care and approved by the Deakin University Animal Ethics
Committee, Deakin University, Geelong.

EXAMPLE 4**Analytical methods**

Whole blood glucose was measured using an enzymatic glucose analyser (Model 27, Yellow
25 Springs Instruments, Ohio). Plasma insulin concentrations were determined using a double
antibody solid phase radioimmunoassay (Phadeseph, Kabi Pharmacia Diagnostics, Sweden).

- 34 -

EXAMPLE 5**Differential display polymerase chain reaction (ddPCR)**

mRNA was extracted from the hypothalamus using a Dynabeads mRNA DIRECT kit (Dyna, Oslo, Norway). The mRNA was reverse transcribed to form cDNA using the oligo-dT primer attached to the beads and AMV reverse transcriptase (Promega, Madison, WI). The ddPCR procedure developed by Liang and Pardee (1992) was modified such that second strand cDNA was produced using arbitrary 13mers and then used for the PCR reaction with the same arbitrary primer and three one-base-anchored oligo-dT primers. All primers were obtained from GenHunter Corporation (Nashville, Tennessee). The sequence of the primers that gave the beacon gene PCR product were 5'-AAGCTTTTTTTTTTTTG-3' [SEQ ID NO:4] (G-anchored primer) and 5'-AAGCTTCGGGTAA-3' [SEQ ID NO:5] (arbitrary primer 11). The 20 µl second strand cDNA synthesis reaction contained 200 nM arbitrary primer, 12.5 µM dNTPs, 100 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin and 1 unit Taq DNA polymerase (Qiagen, Hilden, Germany). Denaturation was performed at 94°C for one minute, annealing at 40°C for 2 minutes and elongation at 72°C for 5 minutes. The reactions were then placed at 94°C for 2 minutes to separate the 2 strands of cDNA and the second strand removed after drawing the first strand attached to magnetic beads to the side of the tube with the use of a magnet. PCR was performed using 2 µl second strand cDNA, 200 nM of each primer, 2 µM dNTPs, 0.2 µl α-[³³P]dATP (2,000 Ci/mmol), 100 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 0.001% w/v gelatin and 1 unit Taq DNA polymerase (Qiagen) in a 20 µl reaction. Amplification was carried out in a Perkin Elmer 9700 DNA thermal cycler for 40 cycles of denaturation at 94°C for 30 seconds, annealing at 40°C for 2 minutes and extension at 72°C for one minute, with a final extension at 72°C for 5 minutes. The PCR products were separated on a 4.5% w/v polyacrylamide gel, and differentially expressed PCR fragments were visualized by exposing the dried gel to x-ray film.

- 35 -

EXAMPLE 6**Band recovery, cloning and sequencing**

Candidate bands were excised from the gel and reamplified by PCR using the appropriate
5 primer combination under the PCR conditions stated above except that the dNTP condition was
20 μ M and no radioisotope was included. The putative differentially expressed cDNA
fragments were cloned using the pCR-TRAP cloning system (GenHunter Corporation).
Sequencing reactions were carried out using ABI PRISM dye terminator cycle sequencing
ready reaction kits and analysed on an ABI 373A DNA sequencer. Gene database searches
10 were performed at the National Centre for Biotechnology Information using the BLAST
network service.

EXAMPLE 7**Quantitation of gene expression**

15

Animals were killed by lethal overdose of pentobarbitone (120 mg/kg) and the following tissues
were removed: liver, spleen, kidney, heart, skeletal muscle (gastrocnemius), and adipose tissue
from the suprascapular, perirenal, intramuscular and mesenteric fat depots. RNA was extracted
from tissues using RNEasy kits (Qiagen, Hilden, Germany). RNA was quantitated by
20 spectrophotometry at 260 nm, and 1 μ g of RNA was then reverse transcribed at 42°C for 1 h
with 10U of AMV Reverse Transcriptase (Boehringer Mannheim, Mannheim, Germany)
according to the manufacturer's instructions. Oligonucleotide primers for the beacon gene PCR
were chosen from the sequence previously determined. Primers were also selected for the beta-
actin gene by comparing mRNA sequences from various mammals to identify highly conserved
25 regions. The primer sequences used were:

beta-actin -	forward 5'- agtccgcggttaagtgaaca -3' [SEQ ID NO:6]
	reverse 5'- ctccaggttcacccatcgt -3' [SEQ ID NO:7]
beacon -	forward 5'-ggctacagcttcaccaccac-3' [SEQ ID NO:8]
	reverse 5'-gcttgctgatccacatctgc-3' [SEQ ID NO:9]

30

- 36 -

PCR was performed by adding 100 ng of cDNA to a reaction mix containing 10 mM Tris-HCl (pH 8.3 at 20°C), 1.5 mM MgCl₂, 50 mM KCl, 200 µM each dNTP, 100 pmol each primer and 1.25 U Taq DNA Polymerase (Qiagen). Standard PCR consisted of 30 cycles of 94°C for 0.5 min (denaturation), 58°C (beta-actin) or 53°C (*beacon*) for 0.5 min (annealing) and 72°C for 1 min (extension), with a final extension step of 72°C for 5 min. 10 µl of each PCR product was fractionated by agarose gel electrophoresis in a 2% w/v gel containing 0.5 µg/ml ethidium bromide at 6 V/cm for 90 min and photographed under ultraviolet transillumination at 302 nm. For quantitation of beacon gene expression, the linear phases of both of the above PCR's were determined empirically as 20 cycles for beta-actin and 24 cycles for *beacon*. PCR's and electrophoresis were conducted as above (for the appropriate number of cycles) and gene expression quantitated by computerised densitometry (Eagle Eye II System, Stratagene, USA). *beacon* gene expression was determined as the ratio of densities of *beacon* to beta-actin PCR products from the same tissues.

15

EXAMPLE 8

Statistical analysis

All experimental data are expressed as means \pm s.e.m. A one-way analysis of variance in combination with a Tukey's multiple comparison test was used to compare means between and within groups, and a two-sample unpaired t-test was used where appropriate. In all instances probability values of <0.05 were considered significant.

EXAMPLE 9

Identification of a body weight-related gene by ddPCR

25

To identify novel genes that are associated with regulation of energy balance, we compared the hypothalamic mRNA profile of lean and obese *Psammomys obesus*. One cDNA fragment amplified with the G-anchored primer and arbitrary primer 11 was found to be expressed in larger amounts in the obese animals. The cDNA band of approximately 400 base pairs was excised from the gel, reamplified and cloned.

- 37 -

EXAMPLE 10**Nucleotide sequence**

Both strands of the differentially expressed band from the obese animals were sequenced. The sequences were identical and are shown in Figure 1A the coding sequence is SEQ ID NO:1 and the complementary sequence is SEQ ID NO:3. The corresponding amino acid sequence is SEQ ID NO:2. This sequence was compared against nucleotide sequence databases and the six-frame conceptual translation products against protein sequence databases. Strong homology was found with genes from humans, mice, *Caenorhabditis elegans*, *Fasciola hepatica*, rice and *Saccharomyces cerevisiae* and weaker homology with ubiquitin and ubiquitin-like proteins. The genes in other species were not named, the inventors called the gene *beacon*. The translation product of the *C. elegans* gene denoted as 'weak similarity to Arabidopsis thaliana ubiquitin-like protein 8' was 81% homologous with beacon and enabled the open reading frame of beacon to be determined. Beacon was found to be 73 amino acids long, the same length as the *C.elegans* gene. Both the start and stop codons were identified within the ddPCR fragment, eliminating the need to probe a cDNA library to determine the full sequence. The full amino acid sequence of beacon is shown in Figure 1 and the amino acid alignments with gene products in humans, mice, *C. elegans*, *F. hepatica*, rice and *S. cerevisiae*, and also human ubiquitin and ubiquitin-like protein 8 from *Arabidopsis thaliana* are shown in Figures 2A and B.

20

The nucleotide sequence and corresponding amino acid sequence for human *beacon* shown in Figure 1B and corresponds to SEQ ID NO:13 and 14, respectively. The human *beacon* sequence substantially corresponds to a short form of the *Psammomys obesus* with the exception that amino acid 15 may be His or Arg and the corresponding codon is CAC or CGC, respectively. In Figure 1B this codon is represented as "CNC" wherein N is preferably A or G.

25

EXAMPLE 11**Analysis of protein**

30 Analysis of the putative protein sequence using ProtParam tool indicated that beacon has a molecular weight of 8503.9 and is a stable protein with an estimated half-life of 30 hours. The

- 38 -

protein does not have an aminoterminal signal sequence often found in proteins destined for export from the cell or for a membrane location. No nuclear targeting signal was found suggesting that beacon is not found in the nucleus. Transmembrane segments were also not found, but beacon may be a peripheral membrane protein, binding to the surface of integral membrane proteins. Beacon appears to have an intramitochondrial signal and may be located within the mitochondrial intermembrane space or the mitochondrial matrix space. Many proteins localized at the mitochondrial inner membrane are likely to be peripheral membrane proteins which exist as members of large membrane complexes. A short form of beacon (33 amino acids) is used in some of the studies. Preliminary human sequence data for *beacon* indicate that in humans, a premature stop codon results in the 33 amino acid short form. The short form comprises the first 33 amino acids of the amino acid sequence given in Figure 1B and 2A for human beacon. Amino acid 15 of human beacon may be His or Arg. The short form is also easier to synthesize chemically.

15

EXAMPLE 12

PCR of the *beacon* gene

PCR primers were designed from the nucleotide sequence of beacon to yield a PCR product of 169 bp. These primers successfully yielded the correct size PCR product with *Psammomys obesus* hypothalamic cDNA. PCR of *Psammomys obesus* genomic DNA yielded the same size product also, indicating that there are no introns within the gene. PCR was also performed on human genomic DNA and the same size product was detected, confirming that the *beacon* gene is also found in humans.

25

EXAMPLE 13

Tissue distribution of *beacon* gene expression in *Psammomys obesus*

The *beacon* gene was expressed at significant levels in all tissues tested in *Psammomys obesus* (hypothalamus, liver, adipose tissue, skeletal muscle (gastrocnemius), heart, pancreas, kidney and spleen).

- 39 -

EXAMPLE 14**Hypothalamic *beacon* gene expression**

Hypothalamic expression of the *beacon* gene was significantly correlated with body weight and plasma insulin concentrations in *Psammomys obesus* (Figure 3). Correlation coefficients of *beacon* gene expression with body weight and plasma insulin were all markedly improved after six days of leptin administration (Figure 4). Neither Adipose tissue *beacon* gene expression or liver *beacon* gene expression were significantly correlated with body weight or circulating insulin levels (Figure 5). Expression of *beacon* was not related to obesity in tissues other than the hypothalamus.

EXAMPLE 15**Leptin treatment**

Leptin treatment resulted in an increase in *beacon* gene expression in the hypothalamus of the group A, lean animals but no difference in the obese group B animals (Figure 6). In contrast *beacon* gene expression in adipose tissue was significantly reduced following leptin treatment in lean animals and similarly unchanged in leptin resistant obese group B animals (Figure 7).

EXAMPLE 16**Nicotine treatment**

Nicotine treatment failed to have any effects on *beacon* gene expression in either hypothalamus or adipose tissue despite significant effects of nicotine treatment on body weight and food intake (Figure 8). These results suggest the effects of leptin treatment on *beacon* gene expression are in fact, independent of body weight and leptin specific.

- 40 -

EXAMPLE 17

Chronic beacon studies

Chronic studies were conducted on three groups of *Psammomys obesus*.

5

The *Psammomys obesus* colony can be classified into three groups based on their blood glucose and insulin levels at 12 weeks of age in the fed state (Barnett *et al*, 1994a). In essence, Group A is a lean group of animals, Group B is an obese, non-diabetic group of animals and Group C is an obese, diabetic group of animals.

10

GROUP A	: NORMOGLYCEMIC	- Glucose	≤ 8 mM
	NORMOINSULINEMIC	- Insulin	≤ 150 mU/mL
GROUP B	: NORMOGLYCEMIC	- Glucose	≤ 8 mM
	HYPERINSULINEMIC	- Insulin	>150 mU/mL
GROUP C	: HYPERGLYCEMIC	- Glucose	> 8 mM
	HYPERINSULINEMIC	- Insulin	> 150 mU/ml

15

20

When compared to normoglycemic and normoinsulinemic Group A animals, Group C *Psammomys obesus* develop a number of abnormalities including hyperglycemia, hyperinsulinemia, increased fat stores, body weight, elevated triglyceride and cholesterol levels and hyperleptinemia (Barnett *et al*, 1994b). These changes represent some of the key features of the metabolic syndrome or Syndrome X.

25

Previous studies have shown that individual animals may progress around the curve in a clockwise direction, from Group A to B to C (Shafir and Gutman, 1993). However the metabolic and physical abnormalities demonstrated in obese Group C *Psammomys obesus* may be corrected by dietary manipulation. Dietary restriction significantly reduces body weight,

30

- 41 -

blood glucose and plasma insulin concentrations (Barnett *et al*, 1994a).

Animals (27 animals total) with ICV cannulas and Alzet pumps were chronically infused with the chemically synthesised short form of beacon (33 amino acids in length, dose = 15ug/day) whilst control animals (28 animals total) were infused with saline. A separate group of animals were treated with neuropeptide Y which is known to increase body weight and food intake. The pumps are designed to deliver solution for 7 days and body weight and food intake were monitored on a daily basis over this time period.

The results are shown in Figures 9-11. Figures 9A-C show a comparison between beacon and saline administration to *Psammomys obesus* as monitored by food intake, cumulative food intake and body weight change. Figures 10A-C show food intake per day for Group A, B and C *Psammomys obesus* administered with beacon or saline. Figures 11A-C show cumulative food intake for Group A, B and C *Psammomys obesus* administered with beacon or saline.

15

The chronic studies indicate that beacon acts in a similar fashion to neuropeptide Y by increasing food intake and body weight. Over the 7-day treatment period of the Alzet pump, food intake/day was increased in beacon treated animals compared to saline controls with a maximal increase (~ 20%) at day 5. Similarly, cumulative food intake and body weight was greater in the beacon treated animals compared to saline controls.

When the animals are divided into groups of A, B and C, it is observed that the increases in body weight and food intake following beacon treatment are more pronounced in the C (n=7) animals. There was little difference in body weight and food intake for beacon treated A (n=9) or B (n=13) animals compared to saline treated B animals (n=13).

25

EXAMPLE 18

beacon gene expression

Studies were conducted to monitor the effects of expression of the *beacon* gene in *P. obesus* *Psammomys obesus*. The results are shown in Figures 12 to 14. The expression of *beacon*

30

- 42 -

increases in all Group A, B and C *Psammomys obesus* with increased body weight or percentage body fat (Figures 12 and 13). Group A animals expressed the highest level of *beacon* (Figure 14) compared to Group B and C animals. These gene expression studies were conducted using a Perkin Elmer "Real-Time" PCR as described below.

5

Real time PCR performed on the ABI Prism 7700 Sequence Detector system consists of a fluorescent-labelled target probe and forward and reverse primers, all of which are specific for the target sequence. The probe is labelled at the 5' end with a reporter dye and at the 3' end with a quencher dye and while the probe is intact the proximity of the quencher reduces the fluorescence emitted by the reporter. The probe anneals downstream from one of the primer sites and as the PCR progresses, the 5' nuclease activity of *Taq* DNA polymerase cleaves the reporter dye from the probe. Once separated from the quencher, the reporter dye emits a characteristic fluorescence.

15 The ABI Prism 7700 Sequence Detector has a built-in thermal cyclor and a laser directed *via* fibre optic cables to each of 96 sample wells. Fluorescence emission data produced during PCR is collected once every few seconds and travels back to the CCD camera detector. Software within the Sequence Detector system analyses the data and amplification plots are produced for each sample allowing us to monitor the entire PCR process for amplification of any specific target sequence. Reactions are categorised by the point in time during cycling when amplification of a product is first detected rather than the amount of product formed after a fixed number of cycles. The higher the amount of target starting material, the sooner a significant increase in fluorescence will be observed.

25 The probe and primer sequences used for the *beacon* gene expression studies are shown below;

Probe 6FAM-TGGTAATAAAGCTCCAGGTTTCATCCCATCG-TAMRA

[SEQ ID NO:10]

(6FAM=fluorescent reporter dye and TAMRA=quencher dye)

30 Forward CAAACTGGCACTCGTTGGAA [SEQ ID NO:11]

Primer

- 43 -

Reverse GTTGGGCAAGGTGGAGGAA [SEQ ID NO:12]
Primer

EXAMPLE 19

5 Effects of insulin on *beacon* gene expression

The effects of insulin on *beacon* gene expression are shown in Figure 15. The data show that increasing levels of insulin results in a decrease in *beacon* gene expression. These results show that *beacon* gene expression is affected in metabolically disturbed animals and insulin retards
10 *beacon* expression.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of
15 the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Barnett M, Collier GR, Collier FM, Zimmet P, O'Dea K (1994a) A cross-sectional and short-term longitudinal characterisation of NIDDM in *Psammomys obesus*. *Diabetologia* 37: 671-676.

Barnett M, Collier GR, Zimmet P, O'Dea K (1994b) The effect of restricting energy intake on diabetes in *Psammomys obesus*. *Int J Obesity* 18: 789-794.

Barnett M, Collier GR, Zimmet P, O'Dea K (1995) Energy intake with respect to the development of diabetes mellitus in *Psammomys obesus*. *Diabete Nutr Metab* 8: 42-47.

Bennett SA, Magnus P (1994) Trends in cardiovascular risk factors in Australia: Results from the National Heart Foundation's Risk Factor Prevalence Study, 1980-1989. *Med J Aust* 161: 519-527.

Bouchard C. The genetics of obesity. Boca Raton: CRC Press, 1994.

Ciechanover A, Schwartz AL (1994) The ubiquitin-mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. *FASEB J* 8: 182-191.

Collier GR, de Silva A, Sanigorski A, Walder K, Yamamoto A, Zimmet P (1997a) Development of obesity and insulin resistance in the Israeli Sand Rat (*Psammomys obesus*): Does leptin play a role. *Ann New York Acad Sci* 827: 50-63.

Collier GR, Walder K, de Silva A, Morton G, Zimmet P (1997b) Diabetes, obesity and leptin in the Israeli Sand Rat (*Psammomys obesus*). *Exp Clin Endocrinol Diabetes* 105: 36-37.

DeFronzo RA (1988) The triumvirate B-cell, muscle and liver: A collusion responsible for NIDDM. *Diabetes* 37: 667-688.

- 45 -

Kopelman PG, Finer N, Fox KR, Hill A, MacDonald IA (1994) ASO consensus statement on obesity. *Int J Obesity* 18: 188-191.

Leibowitz SF (1985) Brain monoamines and peptides: Role in the control of eating behaviour. *Fed Proc* 45: 1396-1403.

Liang P, Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science* 257: 967-971.

National Health and Medical Research Council (1996) Acting on Australia's weight: A strategy for the prevention of overweight and obesity. Canberra: National Health and Medical Research Council.

Needleman and Wunsch (1970) *J. Mol. Biol.* 48: 443-453.

Risk Factor Prevalence Study Management Committee. Risk Factor Prevalence Study: Survey No. 3 1989. Canberra: National Heart Foundation of Australia and Australian Institute of Health, 1990.

Ravussin E (1995) Metabolic differences and the development of obesity. *Metabolism* 44(Suppl 3): 12-14.

Shafir E, Gutman A (1993) *Psammomys obesus* of the Jerusalem colony: A model for nutritionally induced, non-insulin-dependent diabetes. *J Basic Clin Physiol Pharm* 4: 83-99.

Stellar E (1954) The physiology of motivation. *Psychol Rev* 61: 5-22.

Walder K, Dascaluc CR, Lewandowski PA, Sanigorski AJ, Zimmet P, Collier GR (1997a) The effect of dietary energy restriction on the development of obesity and non-insulin-dependent diabetes mellitus (NIDDM) in *Psammomys obesus*. *Obesity Res* 5: 193-200.

- 46 -

Walder K, Lewandowski P, Morton G, Sanigorski A, de Silva A, Zimmet P, Collier GR (1997b) Effects of leptin administration in a polygenic, hyperleptinemic animal model of obesity and NIDDM: *Psammomys obesus*. *Int. J. Obesity* 22: 1-7, 1998.

Waters A-M, Bennett S. Risk Factors for cardiovascular disease: A summary of Australian data. Canberra: Australian Institute of Health and Welfare, 1995.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse *obese* gene and its human homologue. *Nature* 372: 425-432.

Zimmet PZ (1992) Kelly West Lecture: 1991. Challenges in diabetes epidemiology-From West to the Rest. *Diabetes Care* 15(2): 232-247.

- 47 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: (Other than US) INTERNATIONAL DIABETES INSTITUTE and
DEAKIN UNIVERSITY
(US only) G COLLIER and P Z ZIMMET

(ii) TITLE OF INVENTION: A NOVEL GENE AND USES THEREFOR

(iii) NUMBER OF SEQUENCES: 14

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DAVIES COLLISON CAVE

(B) STREET: 1 LITTLE COLLINS STREET

(C) CITY: MELBOURNE

(D) STATE: VICTORIA

(E) COUNTRY: AUSTRALIA

(F) ZIP: 3000

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT INTERNATIONAL

(B) FILING DATE: 30-OCT-1998

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: PP0117/97

(B) FILING DATE: 31-OCT-1997

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: PP0323/97

(B) FILING DATE: 11-NOV-1997

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HUGHES, DR E JOHN L

(C) REFERENCE/DOCKET NUMBER: EJH/AF

- 48 -

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 9254 2777

(B) TELEFAX: +61 3 9254 2770

(C) TELEX: AA 31787

- 49 -

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 342 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 29..247

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTTCCAGGAG ATTACAGCTC CAGCCACA ATG ATT GAG GTG GTT TGC AAC GAC	52
Met Ile Glu Val Val Cys Asn Asp	
1 5	
CGT CTA GGA AAG AAA GTC CGC GTT AAG TGC AAC ACC GAT GAC ACC ATC	100
Arg Leu Gly Lys Lys Val Arg Val Lys Cys Asn Thr Asp Asp Thr Ile	
10 15 20	
GGG GAC TTG AAG AAA CTG ATA GCG GCC CAA ACT GGC ACT CGT TGG AAT	148
Gly Asp Leu Lys Lys Leu Ile Ala Ala Gln Thr Gly Thr Arg Trp Asn	
25 30 35 40	
AAG ATC GTT CTT AAA AAG TGG TAC ACG ATT TTT AAG GAC CAT GTA TCT	196
Lys Ile Val Leu Lys Lys Trp Tyr Thr Ile Phe Lys Asp His Val Ser	
45 50 55	
CTG GGA GAT TAT GAA ATC CAC GAT GGG ATG AAC CTG GAG CTT TAT TAC	244
Leu Gly Asp Tyr Glu Ile His Asp Gly Met Asn Leu Glu Leu Tyr Tyr	
60 65 70	
CAG TAGAGGGGAA TTCCTCCACC TTGCCCAACC TTGCTTTCCT CTCCCATGGC	297
Gln	
TCATTTAACA CTGTTGTAGA TGCTCATTTT TTTGTTAAGT GTACT	342

- 50 -

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 73 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ile Glu Val Val Cys Asn Asp Arg Leu Gly Lys Lys Val Arg Val
 1           5           10           15
Lys Cys Asn Thr Asp Asp Thr Ile Gly Asp Leu Lys Lys Leu Ile Ala
           20           25           30
Ala Gln Thr Gly Thr Arg Trp Asn Lys Ile Val Leu Lys Lys Trp Tyr
           35           40           45
Thr Ile Phe Lys Asp His Val Ser Leu Gly Asp Tyr Glu Ile His Asp
 50           55           60
Gly Met Asn Leu Glu Leu Tyr Tyr Gln
 65           70

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 391 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

ATGTTCAACA CAGCAGCCAT CCAAGGTCCT CTAATGTCGA GGTGGGTGTT ACTAACTCCA      60
CCAAACGTTG CTGGCAGATC CTTTCTTTCA GCGCAATTC ACGTTGTGGC TACTGTGGTA      120
GCCCCTGAAC TTCTTTGACT ATCGCCGGGT TTGACCGTGA GCAACCTTAT TCTAGCAAGA      180
ATTTTTCACC ATGTGCTAAA AATTCCTGGT ACATAGAGAC CCTCTAATAC TTTAGGTGCT      240
ACCCTACTTG GACCTCGAAA TAATGGTCAT CTCCCCTTAA GGAGGTGGAA CGGGTTGGAA      300
CGAAAGGAGA GGGTACCGAG TAAATTGTGA CAACATCTAC GAGTAAAAAA ACAATTCACA      360
TGAATAAAAA CTTTGATGCT GCAAAAAAAA A                                391

```

- 51 -

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAGCTTTTTT TTTTGT

16

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAGCTTCGGG TAA

13

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGTCCGCGTT AAGTGCAACA

20

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTCCAGGTTC ATCCCATCGT

20

- 52 -

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGCTACAGCT TCACCACCAC

20

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCTTGCTGAT CCACATCTGC

20

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TG GTAATAAA GCTCCAGGTT CATCCCATCG

30

- 53 -

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEO ID NO:11:

CAAAC TGGCA CTC GTTGGAA

20

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTTGGGCAAG GTGGAGGAA

19

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 102 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

```
(ix) FEATURE:
      (A) NAME/KEY: CDS
      (B) LOCATION: 1..102
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATG	ATC	GAG	GTT	GTT	TGC	AAC	GAC	CGT	CTG	GGG	AAA	AAG	GTC	CNC	GTT		48
Met	Ile	Glu	Val	Val	Cys	Asn	Asp	Arg	Leu	Gly	Lys	Lys	Val	Xaa	Val		
1				5					10					15			

AAA TGC AAC ACG GAT GAT ACC ATC GGG GAC CTT AAG AAG CTG ATT GCA 96
Lys Cys Asn Thr Asp Asp Thr Ile Gly Asp Leu Lys Lys Leu Ile Ala
20 25 30

GCC TAA
Ala * 102

- 54 -

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Ile Glu Val Val Cys Asn Asp Arg Leu Gly Lys Lys Val Xaa Val
1 5 10 15
Lys Cys Asn Thr Asp Asp Thr Ile Gly Asp Leu Lys Lys Leu Ile Ala
20 25 30
Ala

- 55 -

CLAIMS:

1. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a protein or a derivative, homologue, analogue or mimetic thereof wherein said nucleic acid molecule is expressed in larger amounts in hypothalamus tissue of obese animals compared to lean animals.
2. An isolated nucleic acid molecule according to claim 1 wherein the nucleic acid molecule encodes an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:14 or an amino acid sequence having at least 60% similarity to all or a part thereof or is a mimetic thereof or a nucleotide sequence capable of hybridizing to said nucleic acid molecule under low stringency conditions at 42°C.
3. An isolated nucleic acid molecule according to claim 2 wherein said nucleic acid molecule comprises a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:13 or a nucleotide sequence having at least about 30% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:13 and/or is capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C.
4. An isolated nucleic acid molecule according to claim 3 having the identifying characteristics of the gene "*beacon*".
5. An isolated nucleic acid molecule according to any one of claims 1 to 4 wherein the animal is a human or *Psammomys obesus*.
6. An isolated nucleic acid molecule according to claim 3 ligated or fused to a nucleic acid vector molecule.
7. An isolated protein or a derivative, homologue, analogue or mimetic thereof which is produced in a larger amount in hyperthalamus tissue of obese animals compared to lean animals.

- 56 -

8. An isolated protein according to claim 7 comprising an amino acid sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:14 or an amino acid sequence having at least 30% similarity to all or part of SEQ ID NO:2 or SEQ ID NO:14.

9. An isolated protein according to claim 8 wherein said protein is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or SEQ ID NO:13 or a nucleotide sequence having at least 60% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:13 and/or is capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:13 under low stringency conditions at 42°C.

10. A composition comprising a protein according to any one of claims 7 to 9 or a derivative, homologue, analogue or mimetic thereof or an agonist or antagonist thereof together with one or more pharmaceutically acceptable carriers and/or diluents.

11. A method for treating a subject comprising administering to said subject a treatment effective amount of a protein according to any one of claims 7 to 9 or a derivative, homologue, analogue or mimetic thereof or a genetic sequence encoding same or an agonist or antagonist of said protein or genetic sequence for a time and under conditions sufficient to effect treatment.

12. A method according to claim 11 wherein the treatment is in respect of obesity, anorexia, weight maintenance, energy imbalance, diabetes, metabolic syndrome, dyslipidemia, hypertension and/or insulin resistance.

13. A method of treatment or preventing obesity in a subject, said method comprising administering to said subject an antagonist of beacon or *beacon* gene expression for a time and under conditions sufficient to reduce the levels of beacon in hypothalamus tissue in said subject.

14. An antibody to a protein according to any one of claims 7 to 9 or a derivative, homologue, analogue or mimetic of said protein.

- 57 -

15. An antibody according to claim 14 wherein the antibody is a monoclonal antibody.
16. Use of a protein as defined by any one of claims 7 to 9 or a genetic sequence as defined by any one of claims 1 to 6 in the manufacture of a medicament for the treatment of one or more of obesity, anorexia, energy imbalance or diabetes.
17. A method of detecting beacon or a derivative or homologue thereof in a biological sample, said method comprising contacting said biological sample with an antibody specific for beacon or its antigenic derivatives or homologues for a time and under conditions sufficient for a complex to form and then detecting said complex.
18. A method for detecting expression of *beacon* or its derivatives or homologues in a tissue sample from a subject, said method comprising detecting the presence or amount of *beacon* mRNA in said sample.
19. A method according to claim 17 or 18 for use in determining the risk of development of obesity, anorexia, energy imbalance, diabetes, metabolic syndrome, dyslipidemia, hypertension and/or insulin resistance.

1/25




Fig. 1A

2/25

60

50

K I V L K K W Y T I F K D H V S L G D Y
AAGATCGTCTTAAAGTGTACACGATTTTAAAGGACCATGTATCTCTGGGAGATTAT
TTCTAGCAAGAAATTTTCACCATGTGTGCTAAAAATTCCCTGGTACATAGAGACCCCTCTAATA

70

E I H D G M N L E L Y Y Q STOP
GAAATCCACGATGGGATGAACCTGGAGCTTTATTACCAGTAGAGGGGAATTCCCTCCACC
CTTAGGTGCTACCCCTACTTGGACCTCGAAATAATGGTCATCTCCCTTAAGGAGGTGG

TTGCCCAACCTGCTTTCCTCTCCCATGGCTCATTTAACACTGTTGTAGATGCTCATTTT
AACGGGTTGGAACGAAAGGAGAGGGTACCGAGTAAATTGTGACACAATCTACGAGTAAAAA

AACAATTCACATGAATAAAACTTTGATGCTGCATAAAAAAA 3'

TTGTTAAGTGCTACT 5'

Fig. 1A (i)

3/25

60

50

K I V L K K W Y T I F K D H V S L G D Y
AAGATCGTTC T T A A A A G T G T A C A C G A T T T T A A G G A C C A T G T A T C T C T G G G A G A T T A T
T T C T A G C A A G A A T T T T C A C C A T G T G C T A A A A A T T C C T G G T A C A T A G A G A C C C T C T A A T A

70

E I H D G M N L E L Y Y Q STOP
G A A T C C A C G A T G G A T G A A C C T G G A G C T T T A T T A C C A G T A G A G G G A A T T C C T C C A C C
C T T A G G T G C T A C C C T A C T T G G A C C T C G A A A T A A T G G T C A T C T C C C C T T A A G G A G G T G G

T T G C C C A A C C T T G C T T T C C C T C T C C C A T G G C T C A T T T A A C A C T G T T G T A G A T G C T C A T T T T T
A A C G G G T T G G A A C G A A G A G A G A G G T A C C G A G T A A A T T G T G A C A A C A T C T A C G A G T A A A A A

A A C A A T T C A C A T G A A T A A A A C T T T G A T G C T G C A A A A A A A A A 3'

T T G T T A A G T G T A C T 5'

Fig. 1A (ii)

4/25

ATG ATC GAG GTT GTT TGC AAC GAC CGT CTG GGG AAA AAG GTC CNC 45

Met Ile Glu Val Val Cys Asn Asp Arg Leu Gly Lys Lys Val Xaa

1 5 10 15

GTT AAA TGC AAC ACG GAT GAT ACC ATC GGG GAC CTT AAG AAG CTG 90

Val Lys Cys Asn Thr Asp Asp Thr Ile Gly Asp Leu Lys Lys Leu

20 25 30

102

ATT GCA GCC TAA

Ile Ala Ala *

Fig.1B

5/25




Fig.2A

6/25

AMINO ACID ALIGNMENTS

A.

	10	20	30	40	50
Beacon	*	*	*	*	*
Human	MIEVVCNDR	LGKKVVRV	KCNTDD	TIGDLKKL	IAAQGTGRW
Mouse	MIEVVCNDR	LGKKVVRV	KCNTDD	TIGDLKKL	IAAQGTGRW
C.elegans	MIEITVND	RLGKKVRI	KCNPSD	TIGDLKKL	IAAQGTGRW
F.hepatica	DRLGKKV	RVCNPTD	KVGD	DLKKLIAA	QGTAPERIV
Rice	MIEVVCNDR	LGKKVVRV	KCNTDD	TIGDLKKL	IAAQGTGRW
S.cerev	MIEVVCNDR	LGKKVVRV	KCNTDD	TIGDLKKL	IAAQGTGRW

Fig.2A (i)

7/25

	60	70
Beacon	FKDHVSLGDYEIHDGMNLELYYQ	*
Human	FKDHVSLGDYEIHDGMNLELYYQ	*
Mouse	FKDHVSLGDYEIHDGMNLELYYQ	*
C.elegans	YKDHI TLMDYEIHEGFNFELY YQ	
F.hepatica	YKDHVTLRDYEINDGMNLELYYQ	
Rice	YKDHI TLADYEIHDGMGLELYYN	
S.cerev	LKDHI CLEDYEVHDQTNLELYYL	

Percentage	homologies
Human	73/73 = 100%
Mouse	73/73 = 100%
C.elegans	59/73 = 81%
F.hepatica	54/66 = 82%
Rice	58/73 = 79%
S.cerev	46/73 = 63%

Fig.2A (ii)

8/25




Fig.2B

9/25

३.

Human ubiquitin

10	20	30	40	50
*	*	*	*	*

*
*
*
*
*

Beacon
MIEVVCNDRLGKKVRVKCNTDDTIGDLKKLIAAQGTGRWNKI VLKKWYTI

— + + —
+ —
— + + —
— + + —
— + + —
— + + —

Ugiquitin MQIFVKT LTGKTI TLEVEPSDTIENVKAKIQDKEGIPDPQQRLIFAGKQ

60 70

* * *

Beacon
FKDHVSLGDYEIHDGMNLELYYQ

ubiquitin + + + + +
LEDGRTLSDYNIQKESTLHLVLRGG

Amino acid homology $18/73 = 25\%$

Positives (similar amino acids) $29/73 = 40\%$

Fig. 2B (i)

10/25

Ubiquitin-like protein 8 (A. thaliana)

10	20	30	40	50
*	*	*	*	*

Beacon MIEVVCNDRLGKKVRVKCNTDDTIGDLKKLIAAQGTGRWNKIVLKKWYTI

|| + + + + || || ++ | + | + + + | +

A. thaliana GKTIILEVESSTIANVKEKIQVKEGIKPDDQQMLIFFGQQ

60	70
*	*

Beacon FKDHVSLGDYEIHDGMNLELYYQ

+ | | + | | | + | | |

A. thaliana LEDGVTLGDYDIHKKSTLYL

Amino acid homology 19/60 = 32%

Positives (similar amino acids) 34/60 = 57%

Fig.2B (ii)

11/25




Fig.3A




Fig.3B

12/25




Fig.4A




Fig.4B

13/25




Fig.5A




Fig.5B

14/25




Fig.5C




Fig.5D

15/25




Fig.6






Fig.7

16/25

*Fig.8A**Fig.8B*

17/25




Fig.9A


* = significant, $p < 0.05$

Fig.9B

18/25




Fig.9C




Fig.10A

* = significant, $p < 0.05$

19/25




Fig.10B




Fig.10C

* = significant, $p < 0.05$

20/25




Fig.11A


* = significant, $p < 0.05$

Fig.11B

21/25




Fig.11C

22/25

Beacon v. Body Weight and % Fat in Group A animals




Fig. 12A




Fig. 12B

23/25

Beacon v. % Body Fat




Fig. 13A




Fig. 13B

24/25




Fig. 13C




Fig. 14

 $P < 0.01$ between Group A and BSubstitute Sheet
(Rule 26) RO/AU

25/25




Fig.15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 98/00902

A. CLASSIFICATION OF SUBJECT MATTER					
Int Cl ⁶ : C12N 15/12, C07K 14/00, A61K 38/17					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) SEE ELECTRONIC DATA BOX					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE ELECTRONIC DATA BOX					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPAT: (C07K-014/IC OR C12N-015/IC) AND (NEUROPEPTIDE OR HYPOTHALAMUS) CA MEDLINE:-NEUROPEPTIDE AND HYPOTHALAMUS AND OBESITY; ANGIS - GENPEPT, TREMBL, SWISS-PROT, PIR. SEQUENCE NOS 1, 2 AND 14					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	BRAY, G. A, AM J CLIN NUTR. 1992:5S:265S-715.				
A	FRANKISH, H. M. et al, PEPTIDES.1995; 16(4):757-71				
<div style="display: flex; justify-content: space-between;"> <div style="text-align: center;"> <input type="checkbox"/> Further documents are listed in the continuation of Box C </div> <div style="text-align: center;"> <input type="checkbox"/> See patent family annex </div> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 33%; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> <td style="width: 33%;"></td> </tr> </table>			<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>	
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>				
Date of the actual completion of the international search 25 November 1998		Date of mailing of the international search report - 3 DEC 1998			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer JOHN ASHMAN Telephone No.: (02) 6283 2364			

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/00, A61K 38/17	A1	(11) International Publication Number: WO 99/23217 (43) International Publication Date: 14 May 1999 (14.05.99)
(21) International Application Number: PCT/AU98/00902 (22) International Filing Date: 30 October 1998 (30.10.98) (30) Priority Data: PP 0117 31 October 1997 (31.10.97) AU PP 0323 11 November 1997 (11.11.97) AU (71) Applicants (for all designated States except US): INTERNATIONAL DIABETES INSTITUTE [AU/AU]; 260 Kooyong Road, Caulfield South, VIC 3162 (AU). DEAKIN UNIVERSITY [AU/AU]; Pigdons Road, Waurn Ponds, VIC 3221 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): ZIMMET, Paul, Zev [AU/AU]; 24 Linlithgow Road, Toorak, VIC 3142 (AU). COLLIER, Gregory [AU/AU]; 22 Kestrel Place, Ocean Grove, VIC 3226 (AU). (74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A NOVEL GENE AND USES THEREFOR		
(57) Abstract The present invention relates generally to a nucleic acid molecule which encodes a protein associated with the modulation of obesity, diabetes and metabolic energy levels. More particularly, the present invention is directed to a nucleic acid molecule and a recombinant and purified naturally occurring protein encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecule and protein and their derivatives, homologues, analogues and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.		

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 21118060/EJH	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/AU 98/00902	International filing date (<i>day/month/year</i>) 30 October 1998	(Earliest) Priority Date (<i>day/month/year</i>) 31 October 1997
Applicant INTERNATIONAL DIABETES INSTITUTE AND DEAKIN UNIVERSITY.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of **2** sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international application, the international search was carried out on the basis of the sequence listing:

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (See Box II).

4. With regard to the **title**, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**, ☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ None of the figures

☐ because the applicant failed to suggest a figure

☐ because this figure better characterizes the invention

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 98/00902

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: C12N 15/12, C07K 14/00, A61K 38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
SEE ELECTRONIC DATA BOXDocumentation searched other than minimum documentation to the extent that such documents are included in the fields searched
SEE ELECTRONIC DATA BOXElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPAT: (C07K-014/IC OR C12N-015/IC) AND (NEUROPEPTIDE OR HYPOTHALAMUS)
CA MEDLINE:-NEUROPEPTIDE AND HYPOTHALAMUS AND OBESITY; ANGIS - GENPEPT, TREMBL, SWISS-PROT, PIR. SEQUENCE NOS 1, 2 AND 14**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRAY, G. A, AM J CLIN NUTR. 1992:5S:265S-715.	
A	FRANKISH, H. M. et al, PEPTIDES.1995; 16(4):757-71	

☐ Further documents are listed in the continuation of Box C☐ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
25 November 1998Date of mailing of the international search report
- 3 DEC 1998Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606
AUSTRALIA
Facsimile No.: (02) 6285 3929

Authorized officer

JOHN ASHMAN

Telephone No.: (02) 6283 2364